Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• Regdanvimab (CT-P59) demonstrated efficacy in reducing hospitalization and death in mild-to-moderate COVID-19 patients during Phase III trials.
• This study investigates the real-world effectiveness of regdanvimab in managing COVID-19 symptoms and progression.

Purpose of the Study:

• To evaluate the impact of regdanvimab compared to standard of care (SoC) on oxygen saturation levels in patients with COVID-19.
• To assess the clinical outcomes and treatment patterns associated with regdanvimab use in a real-world setting.

Main Methods:

• A retrospective cohort study was conducted on patients diagnosed with mild-to-moderate COVID-19 via RT-PCR.
• The primary endpoint was the incidence of peripheral capillary oxygen saturation (SpO2) <94% on room air up to day 28 post-treatment.
• Patient data included oxygen saturation, fever recovery, hospitalization duration, and need for supplemental oxygen or mechanical ventilation.

Main Results:

• Regdanvimab treatment resulted in a significantly lower proportion of patients experiencing SpO2 deterioration (13.4%) compared to SoC (39.5%).
• Fewer patients receiving regdanvimab required supplemental oxygen (23.6% vs. 52.1%) or remdesivir (14.2% vs. 43.2%).
• Hospitalization duration was shorter for regdanvimab recipients, with no reported deaths or need for mechanical ventilation.

Conclusions:

• Regdanvimab effectively prevents clinical deterioration, evidenced by improved oxygen saturation levels in mild-to-moderate COVID-19 patients.
• The real-world data supports regdanvimab as a valuable therapeutic option for managing COVID-19, reducing the need for oxygen support and shortening hospital stays.